Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website


Insmed reported $187.98M in Current Liabilities for its fiscal quarter ending in March of 2023.

Current Liabilities Change
Alimera Sciences ALIM:US USD 14.17M 25.56M
BioMarin Pharmaceutical BMRN:US USD 598.23M 9.35M
Cytokinetics CYTK:US USD 75.22M 9.4M
DBV Technologies DBVT:US USD 32.78M 3.26M
Dynavax Technologies DVAX:US USD 91.52M 58.56M
Gilead Sciences GILD:US USD 10.53B 709M
Heron Therapeutics HRTX:US USD 77.9M 4.46M
Insmed INSM:US USD 187.98M 2.26M
Iveric bio Inc. OPHT:US USD 39.37M 3.79M
Mirati Therapeutics MRTX:US USD 124.6M 34.85M
Novartis NVS:US USD 30.55B 1.89B
Regeneron Pharmaceuticals REGN:US USD 3.1B 41.2M
Sarepta Therapeutics SRPT:US USD 536.88M 82.72M
Seattle Genetics SGEN:US USD 713.23M 105.18M
Ultragenyx Pharmaceutical RARE:US USD 218.18M 43.03M
Vertex Pharmaceuticals VRTX:US USD 3.03B 284.1M